China, Brazil Should Not Be In AIDS Drug Patent Pool, Gilead Says
This article was originally published in PharmAsia News
Executive Summary
HONG KONG - The number of partnerships among multinational pharmaceutical companies for HIV/AIDS drugs is on the rise, driven in part by the growing need for combination products to which no single company owns all the patents